TCGA-BB-4224-01A-01R-1436-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.500
- SPERMATOGENESIS+0.320
- G2M_CHECKPOINT+0.290
- PANCREAS_BETA_CELLS+0.200
- KRAS_SIGNALING_DN+0.150
- MYC_TARGETS_V1+0.140
- DNA_REPAIR+0.010
- BILE_ACID_METABOLISM-0.030
- OXIDATIVE_PHOSPHORYLATION-0.040
- PEROXISOME-0.070
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.610
- TNFA_SIGNALING_VIA_NFKB-0.550
- IL6_JAK_STAT3_SIGNALING-0.530
- INFLAMMATORY_RESPONSE-0.530
- HEDGEHOG_SIGNALING-0.510
- INTERFERON_GAMMA_RESPONSE-0.500
- ANDROGEN_RESPONSE-0.490
- TGF_BETA_SIGNALING-0.490
- ANGIOGENESIS-0.480
- IL2_STAT5_SIGNALING-0.460
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_61E80SD6 | medulloblastoma | — | 0.939 |
| 2 | BS_KN92S7YQ | medulloblastoma | — | 0.933 |
| 3 | BS_ERWT0ZWE | medulloblastoma | — | 0.931 |
| 4 | TCGA-FJ-A3ZF-01A-11R-A23N-07 | — | — | 0.931 |
| 5 | BS_3NWQXPQV | medulloblastoma | — | 0.930 |
| 6 | BS_W9AT0MR7 | medulloblastoma | — | 0.928 |
| 7 | BS_W311713R | medulloblastoma | — | 0.928 |
| 8 | BS_5PJCHF6V | medulloblastoma | — | 0.927 |
| 9 | SRR10842347 | — | — | 0.925 |
| 10 | BS_7FWZ518S | medulloblastoma | — | 0.924 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 7 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.320 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.290 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.150 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.140 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.010 | Idelalisib | — uncovered |